Published in Eur J Nucl Med Mol Imaging on June 11, 2013
Vessel caliber--a potential MRI biomarker of tumour response in clinical trials. Nat Rev Clin Oncol (2014) 0.93
(18)F-fluorothymidine PET imaging in gliomas: an update. Ann Nucl Med (2017) 0.77
Assessment of bevacizumab resistance increased by expression of BCAT1 in IDH1 wild-type glioblastoma: application of DSC perfusion MR imaging. Oncotarget (2016) 0.75
Mechanistic interrogation of combination bevacizumab/dual PI3K/mTOR inhibitor response in glioblastoma implementing novel MR and PET imaging biomarkers. Eur J Nucl Med Mol Imaging (2016) 0.75
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Fiji: an open-source platform for biological-image analysis. Nat Methods (2012) 56.92
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (1993) 15.70
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol (2009) 14.15
Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging (1999) 13.26
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res (2007) 9.21
Angiogenesis in brain tumours. Nat Rev Neurosci (2007) 6.82
Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A (2011) 3.48
The use of power images to perform quantitative analysis on low SNR MR images. Magn Reson Imaging (1993) 3.18
Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol (2007) 2.77
Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol (2006) 2.72
NMR imaging of changes in vascular morphology due to tumor angiogenesis. Magn Reson Med (1998) 2.08
Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells. Clin Cancer Res (2011) 2.06
Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc Natl Acad Sci U S A (2006) 1.96
Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol (2010) 1.87
Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer (2009) 1.80
Imaging of integrin alphavbeta3 expression. Cancer Metastasis Rev (2008) 1.56
Correlation of L-methyl-11C-methionine (MET) uptake with L-type amino acid transporter 1 in human gliomas. J Neurooncol (2010) 1.48
18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med (2005) 1.44
Analytical model of susceptibility-induced MR signal dephasing: effect of diffusion in a microvascular network. Magn Reson Med (1999) 1.24
MR imaging of microvasculature. Magn Reson Med (2000) 1.23
Interdependency of local capillary density, blood flow, and metabolism in rat brains. Am J Physiol (1986) 1.23
3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med (2011) 1.18
Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms. Expert Opin Ther Targets (2009) 1.09
Methyl-[11C]- l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging (2003) 1.06
Assessment of vascularity in histological sections: effects of methodology and value as an index of angiogenesis in breast tumours. Histochem J (1998) 0.97
High-resolution MR imaging of mouse brain microvasculature using the relaxation rate shift index Q. NMR Biomed (2004) 0.96
Vessel size index measurements in a rat model of glioma: comparison of the dynamic (Gd) and steady-state (iron-oxide) susceptibility contrast MRI approaches. NMR Biomed (2011) 0.89
The inclusion of capillary distribution in the adiabatic tissue homogeneity model of blood flow. Phys Med Biol (2001) 0.88
Analysis of the growth dynamics of angiogenesis-dependent and -independent experimental glioblastomas by multimodal small-animal PET and MRI. J Nucl Med (2012) 0.86
Mouse models in neurological disorders: applications of non-invasive imaging. Biochim Biophys Acta (2010) 0.85
In-vivo visualization of tumor microvessel density and response to anti-angiogenic treatment by high resolution MRI in mice. PLoS One (2011) 0.83
Regional and directional anisotropy of apparent diffusion coefficient in rat brain. NMR Biomed (1999) 0.79
Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med (2003) 3.10
Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol (2005) 2.65
Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci U S A (2004) 2.54
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. J Clin Oncol (2011) 2.10
Cellular MR imaging. Mol Imaging (2005) 2.01
Host-dependent tumorigenesis of embryonic stem cell transplantation in experimental stroke. J Cereb Blood Flow Metab (2003) 2.01
Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol (2010) 1.87
A fully noninvasive and robust experimental protocol for longitudinal fMRI studies in the rat. Neuroimage (2005) 1.81
Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol (2003) 1.50
Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res (2004) 1.48
Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J Neurosci (2006) 1.46
3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res (2002) 1.46
Multiple sclerosis: myeloperoxidase immunoradiology improves detection of acute and chronic disease in experimental model. Radiology (2014) 1.46
Molecular imaging of proliferation in malignant lymphoma. Cancer Res (2006) 1.46
Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. J Clin Invest (2013) 1.41
Investigation of insect morphology by MRI: assessment of spatial and temporal resolution. Magn Reson Imaging (2002) 1.38
Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma. Clin Cancer Res (2008) 1.36
In vivo optical imaging of neurogenesis: watching new neurons in the intact brain. Mol Imaging (2008) 1.34
Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med (2006) 1.33
Pathophysiological changes of the gastrointestinal tract in ischemic stroke. Am J Gastroenterol (2006) 1.32
O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. J Nucl Med (2011) 1.30
[18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. Neuro Oncol (2013) 1.30
Crossed cerebellar diaschisis in acute human stroke: a PET study of serial changes and response to supratentorial reperfusion. J Cereb Blood Flow Metab (2005) 1.29
Bystander killing of malignant glioma by bone marrow-derived tumor-infiltrating progenitor cells expressing a suicide gene. Mol Ther (2007) 1.29
Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer. Mol Imaging Biol (2015) 1.26
Early prediction of functional recovery after experimental stroke: functional magnetic resonance imaging, electrophysiology, and behavioral testing in rats. J Neurosci (2008) 1.24
Temporal profile of T2-weighted MRI distinguishes between pannecrosis and selective neuronal death after transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab (2006) 1.23
Mutant sodium channel for tumor therapy. Mol Ther (2009) 1.22
3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease. Cancer Res (2003) 1.21
Differences in clot preparation determine outcome of recombinant tissue plasminogen activator treatment in experimental thromboembolic stroke. Stroke (2003) 1.20
Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET). PLoS One (2008) 1.16
Stem cell mediation of functional recovery after stroke in the rat. PLoS One (2010) 1.15
Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging (2002) 1.15
Value of gradient-echo magnetic resonance imaging in the diagnosis of familial cerebral cavernous malformation. Arch Neurol (2005) 1.15
Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment. Mol Pharmacol (2006) 1.14
Differential SELEX in human glioma cell lines. PLoS One (2009) 1.13
Current status of functional MRI on small animals: application to physiology, pathophysiology, and cognition. NMR Biomed (2007) 1.12
Metabolic differences between primary and recurrent human brain tumors: a 1H NMR spectroscopic investigation. NMR Biomed (2005) 1.11
Neuroinflammation extends brain tissue at risk to vital peri-infarct tissue: a double tracer [11C]PK11195- and [18F]FDG-PET study. J Cereb Blood Flow Metab (2009) 1.11
Differential effects of NMDA and AMPA glutamate receptors on functional magnetic resonance imaging signals and evoked neuronal activity during forepaw stimulation of the rat. J Neurosci (2006) 1.11
Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT. Eur J Nucl Med Mol Imaging (2007) 1.10
In vivo tracking of human neural stem cells with 19F magnetic resonance imaging. PLoS One (2011) 1.09
Functional uncoupling of hemodynamic from neuronal response by inhibition of neuronal nitric oxide synthase. J Cereb Blood Flow Metab (2006) 1.09
Present status of magnetic resonance imaging and spectroscopy in animal stroke models. J Cereb Blood Flow Metab (2006) 1.09
Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET. J Nucl Med (2011) 1.08
Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors. Sci Transl Med (2013) 1.05
High field BOLD response to forepaw stimulation in the mouse. Neuroimage (2010) 1.04
Noninvasive imaging of endogenous neural stem cell mobilization in vivo using positron emission tomography. J Neurosci (2010) 1.04
Labeling cells for in vivo tracking using (19)F MRI. Biomaterials (2012) 1.04
Volumetry of [(11)C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme. Eur J Nucl Med Mol Imaging (2010) 1.03
Direct comparison of [18F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanoma. Eur J Nucl Med Mol Imaging (2007) 1.03
Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. Eur J Nucl Med Mol Imaging (2006) 1.03
MRI detection of macrophage activity after experimental stroke in rats: new indicators for late appearance of vascular degradation? Magn Reson Med (2005) 1.03
Ischaemic tolerance: a window to endogenous neuroprotection? Lancet (2003) 1.03
Noninvasive quantification of 18F-FLT human brain PET for the assessment of tumour proliferation in patients with high-grade glioma. Eur J Nucl Med Mol Imaging (2009) 1.02
Methods to monitor gene therapy with molecular imaging. Methods (2009) 1.02
Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib. Eur J Nucl Med Mol Imaging (2012) 1.02
Boosting bioluminescence neuroimaging: an optimized protocol for brain studies. PLoS One (2013) 1.01
Herpes simplex virus 1 amplicon vector-mediated siRNA targeting epidermal growth factor receptor inhibits growth of human glioma cells in vivo. Mol Ther (2005) 1.01
MRI detection of secondary damage after stroke: chronic iron accumulation in the thalamus of the rat brain. Stroke (2008) 0.99
Thrombolytic treatment of clot embolism in rat: comparison of intra-arterial and intravenous application of recombinant tissue plasminogen activator. Stroke (2002) 0.98
Stem cell implantation in ischemic mouse heart: a high-resolution magnetic resonance imaging investigation. NMR Biomed (2005) 0.98
Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3'-[(18)F]fluoro-3'-deoxythymidine ([(18)F]FLT) in pancreatic cancer cell lines. Eur J Nucl Med Mol Imaging (2002) 0.98
Clinical relevance of imaging proliferative activity in lung nodules. Eur J Nucl Med Mol Imaging (2004) 0.97
Cholinergic system function and cognition in mild cognitive impairment. Neurobiol Aging (2010) 0.97
Multicolor fluorescence imaging of traumatic brain injury in a cryolesion mouse model. ACS Chem Neurosci (2012) 0.97
Multimodal imaging of neural progenitor cell fate in rodents. Mol Imaging (2008) 0.96
Functional connectivity in the rat at 11.7T: Impact of physiological noise in resting state fMRI. Neuroimage (2010) 0.96
Improved stem cell MR detectability in animal models by modification of the inhalation gas. Mol Imaging (2005) 0.96
Time course of circulatory and metabolic recovery of cat brain after cardiac arrest assessed by perfusion- and diffusion-weighted imaging and MR-spectroscopy. Resuscitation (2003) 0.95
Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma. J Nucl Med (2009) 0.94
[11C]-L-methionine positron emission tomography in the management of children and young adults with brain tumors. J Neurooncol (2009) 0.94
The translocator protein ligand [¹⁸F]DPA-714 images glioma and activated microglia in vivo. Eur J Nucl Med Mol Imaging (2012) 0.94
Central nervous system inflammatory response after cerebral infarction as detected by magnetic resonance imaging. NMR Biomed (2004) 0.93
Anti-CD45 monoclonal antibody YAML568: A promising radioimmunoconjugate for targeted therapy of acute leukemia. J Nucl Med (2006) 0.92
Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib. Clin Nucl Med (2012) 0.92
Spatio-temporal dynamics, differentiation and viability of human neural stem cells after implantation into neonatal rat brain. Eur J Neurosci (2011) 0.92
188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study. Br J Haematol (2005) 0.91
NUMB does not impair growth and differentiation status of experimental gliomas. Exp Cell Res (2011) 0.90
Stem cell labeling for magnetic resonance imaging. Minim Invasive Ther Allied Technol (2008) 0.90
Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib. PLoS One (2013) 0.90
A Critical Re-Examination of the Intraluminal Filament MCAO Model: Impact of External Carotid Artery Transection. Transl Stroke Res (2011) 0.90
Histochemical detection of ultrasmall superparamagnetic iron oxide (USPIO) contrast medium uptake in experimental brain ischemia. Magn Reson Med (2004) 0.89
Evaluating reporter genes of different luciferases for optimized in vivo bioluminescence imaging of transplanted neural stem cells in the brain. Contrast Media Mol Imaging (2013) 0.89
Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma. Mol Imaging (2010) 0.89
Brain maturation of the adolescent rat cortex and striatum: changes in volume and myelination. Neuroimage (2013) 0.88
Imaging of non- or very subtle contrast-enhancing malignant gliomas with [¹¹C]-methionine positron emission tomography. Mol Imaging (2011) 0.88
The translocator protein radioligand 18F-DPA-714 monitors antitumor effect of erufosine in a rat 9L intracranial glioma model. J Nucl Med (2013) 0.88
Altered cerebral glucose metabolism in a family with clinical features resembling mitochondrial neurogastrointestinal encephalomyopathy syndrome in association with multiple mitochondrial DNA deletions. Arch Neurol (2008) 0.88
Copper-mediated aromatic radiofluorination revisited: efficient production of PET tracers on a preparative scale. Chemistry (2015) 0.87